NCT00940316 - Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 18, 2010

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Colorectal Cancer

Interventions

BIOLOGICAL

panitumumab

Given intravenously 6mg/kg every 2 weeks

DRUG

erlotinib hydrochloride

Given orally 150mg daily

DRUG

irinotecan hydrochloride

Given intravenously 120mg/m2 for 6/6 genotype and 60mg/m2 for 6/7 genotype

Trial Locations (10)

The Jones Clinic, Germantown

Hope Cancer Center, Terre Haute

Cancer Care & Hematology Specialists of Chicagoland, Arlington Heights

Joliet Oncology-Hematology Associates, Ltd., Joliet

Hematology/Oncology Associates, Chicago

Cancer Center of Kansas, Wichita

Nebraska Methodist Hospital, Omaha

Northwestern University, Northwestern Medical Faculty Foundation, Chicago

Virtua Memorial (Regional Cancer Care Associates of Mount Holly), Mount Holly

Mercy Clinic Oncology and Hematology, Oklahoma City